WMA appoints Canadian president
This article was originally published in Scrip
Executive Summary
Dr Dana Hanson has been elected president of the World Medical Associationfor 2009-10, the first Canadian to be appointed in over 35 years. Dr Hanson will use his presidency to focus on patient and physician advocacy, health and the environment. The position will become effective in a years' time, when Dr Hanson will take over from Dr Yoram Blachar, president of the Israel Medical Association, who holds the position for 2008-09. The last Canadian to be elected president was Dr Arthur Peart, secretary general of the Canadian Medical Association, in 1971.
You may also be interested in...
How to leverage India: Five up-and-coming domestic players
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Active Biotech appoints CSO
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed appoints new chief commercial officer
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).